New York, July 6, 2026, 11:08 (EDT)
- HSBC cut Pfizer to Hold from Buy and lowered its target to $28 from $32.
- Pfizer shares were down about 2.7% at $23.665 in morning trade.
- At that price, Pfizer’s $1.72 annualized dividend yields about 7.3%.
- The dividend uses about 57%-61% of Pfizer’s 2026 adjusted EPS guidance.
Pfizer Inc NYSE:PFE fell in Monday morning trade after HSBC Holdings (LON:HSBA) cut its rating, but the sharper investor question is now dividend cover, not only the downgrade. The stock traded at $23.665 at 10:53 a.m. EDT, down about 2.7%, giving Pfizer a market value of about $135.6 billion.
Pfizer’s board declared a third-quarter dividend of 43 cents a share, payable Sept. 1 to holders of record as of July 24. Annualized, that is $1.72 a share. Against Pfizer’s 2026 adjusted diluted EPS guidance of $2.80 to $3.00, the payout uses about 57% to 61% of guided adjusted earnings. Pfizer
The notable read-through from HSBC analyst Rajesh Kumar’s same-day pharma calls is that Pfizer’s target upside did not stand out as low. Pfizer was cut to Hold even though its implied upside sat near Merck and AbbVie, which HSBC kept at Buy. That points to catalyst quality, not a simple valuation gap.
| Company | HSBC action | Target move | Implied upside shown |
|---|---|---|---|
| CVS Health NYSE:CVS | Hold maintained | $103 | -0.06% |
| Merck & Co NYSE:MRK | Buy maintained | $120 to $150 | +19.16% |
| Pfizer Inc NYSE:PFE | Cut to Hold | $32 to $28 | +18.47% |
| Regeneron Pharmaceuticals NASDAQ:REGN | Buy maintained | $800 | +25.15% |
| AbbVie Inc NYSE:ABBV | Buy maintained | $265 to $300 | +17.24% |
HSBC lowered its view of the probability to market for sigvotatug vedotin to 40% after the Phase 3 setback in non-small cell lung cancer. It also raised its beta assumption to 0.85 from 0.78 and cited fewer near-term rerating catalysts, according to Investing.com.
| Pfizer item | Data point | Investor read |
|---|---|---|
| Live share price | $23.665 | Stock sits close to its recent low range |
| New HSBC target | $28 | About 18.3% above the live quote |
| Old HSBC target | $32 | About 35.2% above the live quote |
| Target cut | $4 a share | 12.5% lower |
| Annualized dividend | $1.72 | About 7.3% yield at $23.665 |
| 2026 adjusted EPS guide | $2.80-$3.00 | Dividend uses about 57%-61% of guided adjusted EPS |
The downgrade followed Pfizer’s own late-June trial readout. SigVie-002 enrolled 703 participants and did not show a statistically significant improvement in overall survival versus docetaxel in the overall population. Pfizer said the second-line subgroup, about two-thirds of the study, showed a stronger trend in survival and progression-free survival. Jeff Legos, Pfizer’s chief oncology officer, said “there is clearly more work to be done.” Solange Peters of Lausanne University Hospital said the second-line data suggest a “clinically meaningful survival benefit.” Pfizer
Pfizer still has an offset in breast cancer. The FDA approved Ibrance with trastuzumab, with or without pertuzumab, and endocrine therapy for maintenance treatment of HR-positive, HER2-positive locally advanced or metastatic breast cancer after induction treatment. The 518-patient PATINA trial showed a progression-free-survival hazard ratio of 0.76, while overall survival data were not mature.
Aamir Malik, Pfizer’s chief U.S. commercial officer, said the approval made Ibrance the first CDK4/6 inhibitor for HR-positive metastatic breast cancer regardless of HER2 status. The company said PATINA showed a 24% reduction in the risk of progression or death with Ibrance added to anti-HER2 and endocrine therapy.
The technical setup leaves little room for delay. A July 6 technical note put Pfizer below its 20-day, 50-day and 200-day exponential moving averages, with the stock at $23.67 at the time. Using the latest $23.665 quote, the stock would need to regain about 4.7% to reach the 20-day EMA and about 8.5% to reach the 200-day EMA.
| Reference level | Level cited | Gain needed from $23.665 |
|---|---|---|
| 20-day EMA | $24.77 | 4.7% |
| 50-day EMA | $25.50 | 7.8% |
| 200-day EMA | $25.68 | 8.5% |
| HSBC target | $28.00 | 18.3% |
Pfizer’s first-quarter revenue rose 5% to $14.45 billion, but adjusted diluted EPS fell 18% to 75 cents. CFO David Denton said Pfizer was “reaffirming our full-year 2026 financial guidance.” The company said guidance assumes no share repurchases in 2026. Business Wire
Related articles: NYSE:PFE
